Equities Analysts Set Expectations for KRMD FY2024 Earnings

KORU Medical Systems, Inc. (NASDAQ:KRMD) – Stock analysts at B. Riley lifted their FY2024 earnings per share (EPS) estimates for KORU Medical Systems in a report issued on Tuesday, January 14th. B. Riley analyst K. Bauser now forecasts that the company will post earnings of ($0.13) per share for the year, up from their prior estimate of ($0.14). The consensus estimate for KORU Medical Systems’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for KORU Medical Systems’ Q4 2024 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.09) EPS.

Several other research analysts have also recently issued reports on KRMD. Piper Sandler increased their price target on KORU Medical Systems from $3.00 to $3.50 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Canaccord Genuity Group raised their target price on shares of KORU Medical Systems from $3.00 to $4.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Craig Hallum boosted their price target on shares of KORU Medical Systems from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. Finally, Lake Street Capital increased their price objective on shares of KORU Medical Systems from $4.00 to $5.00 and gave the company a “buy” rating in a report on Tuesday. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $4.30.

KORU Medical Systems Price Performance

Shares of KRMD stock opened at $3.94 on Thursday. The business has a 50 day simple moving average of $3.75 and a 200 day simple moving average of $2.95. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.99 and a quick ratio of 2.37. KORU Medical Systems has a 12-month low of $1.98 and a 12-month high of $4.60.

Institutional Investors Weigh In On KORU Medical Systems

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Meros Investment Management LP grew its stake in shares of KORU Medical Systems by 20.7% in the 2nd quarter. Meros Investment Management LP now owns 804,380 shares of the company’s stock worth $2,132,000 after purchasing an additional 137,918 shares during the last quarter. Geode Capital Management LLC boosted its holdings in KORU Medical Systems by 6.5% during the third quarter. Geode Capital Management LLC now owns 462,128 shares of the company’s stock worth $1,262,000 after buying an additional 28,323 shares in the last quarter. Empire Financial Management Company LLC bought a new stake in KORU Medical Systems during the third quarter worth approximately $259,000. Connor Clark & Lunn Investment Management Ltd. grew its position in KORU Medical Systems by 77.7% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 61,412 shares of the company’s stock worth $168,000 after buying an additional 26,860 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of KORU Medical Systems in the second quarter valued at $107,000. 58.60% of the stock is currently owned by institutional investors.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.